DK3320099T3 - Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer - Google Patents
Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer Download PDFInfo
- Publication number
- DK3320099T3 DK3320099T3 DK16738128.4T DK16738128T DK3320099T3 DK 3320099 T3 DK3320099 T3 DK 3320099T3 DK 16738128 T DK16738128 T DK 16738128T DK 3320099 T3 DK3320099 T3 DK 3320099T3
- Authority
- DK
- Denmark
- Prior art keywords
- anchored
- membrane
- expression
- lentiviral vectors
- secreted antibody
- Prior art date
Links
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15306132 | 2015-07-09 | ||
PCT/EP2016/066349 WO2017005923A1 (en) | 2015-07-09 | 2016-07-08 | Lentiviral vector expressing membrane-anchored or secreted antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3320099T3 true DK3320099T3 (da) | 2023-12-11 |
Family
ID=53673045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16738128.4T DK3320099T3 (da) | 2015-07-09 | 2016-07-08 | Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer |
Country Status (5)
Country | Link |
---|---|
US (2) | US11623950B2 (da) |
EP (1) | EP3320099B1 (da) |
DK (1) | DK3320099T3 (da) |
ES (1) | ES2965292T3 (da) |
WO (1) | WO2017005923A1 (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2019170677A1 (en) * | 2018-03-05 | 2019-09-12 | Etablissement Francais Du Sang | Recombinant single chain immunoglobulins |
WO2020053865A1 (en) * | 2018-09-13 | 2020-03-19 | Ramot At Tel-Aviv University Ltd. | Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion |
CN117425725A (zh) * | 2021-02-07 | 2024-01-19 | 贝勒医学院 | 用于扩增和体内保存的工程化nkt细胞以及用于控制肿瘤细胞的方法 |
WO2022251712A1 (en) * | 2021-05-28 | 2022-12-01 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
TW202334405A (zh) * | 2021-12-15 | 2023-09-01 | 美商英特瑞斯生物療法公司 | 假型分型之病毒顆粒、包含其之組合物及其用途 |
WO2023133595A2 (en) * | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1652920E (pt) * | 2001-10-01 | 2010-11-08 | Deutsches Krebsforsch | Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma |
WO2003068819A1 (en) * | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
WO2006042158A2 (en) * | 2004-10-05 | 2006-04-20 | Wyeth | Methods and compositions for improving recombinant protein production |
US7878409B2 (en) * | 2005-12-09 | 2011-02-01 | Shoplogix Inc. | System and method for verifying identity during data entry with a barcode scanner |
EP2208792B1 (en) * | 2006-05-17 | 2015-05-06 | Hoffmann-La Roche AG | Polypeptide producing cells |
WO2008070367A2 (en) * | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
US7947495B2 (en) * | 2007-11-01 | 2011-05-24 | Abbott Biotherapeutics Corp. | Immunoglobulin display vectors |
US8969539B2 (en) * | 2008-06-11 | 2015-03-03 | Jn Biosciences Llc | Expression vectors |
US8529903B2 (en) * | 2008-12-31 | 2013-09-10 | Bharat Serums And Vaccines Ltd. | Anti-RhD monoclonal antibodies |
US20100303776A1 (en) * | 2009-04-16 | 2010-12-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of multiple nucleic acids |
US8680241B2 (en) * | 2009-09-06 | 2014-03-25 | Protab Ltd. | Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof |
CA2793309A1 (en) * | 2010-03-17 | 2011-09-22 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
US20170350886A1 (en) * | 2014-02-28 | 2017-12-07 | Glenmark Pharmaceuticals S.A. | Expression constructs and methods for selecting host cells expressing polypeptides |
-
2016
- 2016-07-08 WO PCT/EP2016/066349 patent/WO2017005923A1/en active Application Filing
- 2016-07-08 EP EP16738128.4A patent/EP3320099B1/en active Active
- 2016-07-08 US US15/742,909 patent/US11623950B2/en active Active
- 2016-07-08 ES ES16738128T patent/ES2965292T3/es active Active
- 2016-07-08 DK DK16738128.4T patent/DK3320099T3/da active
-
2023
- 2023-02-24 US US18/174,182 patent/US20230340085A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11623950B2 (en) | 2023-04-11 |
EP3320099B1 (en) | 2023-09-13 |
US20230340085A1 (en) | 2023-10-26 |
WO2017005923A1 (en) | 2017-01-12 |
EP3320099A1 (en) | 2018-05-16 |
ES2965292T3 (es) | 2024-04-12 |
US20180371064A1 (en) | 2018-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3538965T3 (da) | Sikkerhedssystem til drift af et ubemandet luftfartøj | |
CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
DK3320099T3 (da) | Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer | |
DK3371619T3 (da) | Detektering af et ubemandet luftfartøj | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
DK3331876T3 (da) | Modulators of ror-gamma | |
DK3277717T3 (da) | En hidtil ukendt il33-form, muterede former af il33, antistoffer, assays og fremgangsmåder til anvendelse deraf | |
DK3538864T3 (da) | Mikrotom | |
DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
DK3259349T3 (da) | Dehydrogenase-katalyseret fremstilling af FDCA | |
DK3563156T3 (da) | Fremgangsmåde til separering af biomolekyler | |
DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
DK3377618T3 (da) | Buffere til stabilisering af lentivirus-præparater | |
DK3287523T3 (da) | Fremgangsmåde til sekretorisk fremstilling af protein | |
DK3458100T3 (da) | Selektiv reduktion af cystein-manipulerede antistoffer | |
DK3515990T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
DK3487443T3 (da) | Fremgangsmåde til opmåling af en implantat-implantat-situation | |
DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
DK3148642T3 (da) | Anordning til profylakse af hørenedsættelse eller vertigo | |
DK3201346T3 (da) | Fremgangsmåder til fremstilling af biopolymer-matrix kompositmaterialer |